Misplaced Pages

Envafolimab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Cancer immunotherapy medication

Pharmaceutical compound
Envafolimab
Monoclonal antibody
TypeSingle-chain variable fragment
TargetPD-L1
Clinical data
Drug classAntineoplastic agent
ATC code
  • None
Identifiers
CAS Number
PubChem CID
DrugBank
UNII

Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy. It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours. Envafolimab (KN035) has obtained the US FDA's orphan drug designation for advanced biliary tract cancer.

References

  1. "Envafolimab - Alphamab Oncology/Ascletis/3D Medicine". AdisInsight. Springer Nature Switzerland AG.
  2. Markham A (February 2022). "Envafolimab: First Approval". Drugs. 82 (2): 235–240. doi:10.1007/s40265-022-01671-w. PMID 35122636. S2CID 246534311.
Targeted cancer therapy / antineoplastic agents (L01)
CI monoclonal antibodies ("-mab")
Receptor tyrosine kinase
Others for solid tumors
Leukemia/lymphoma
Other
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
Non-receptor
Other
Portal:


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Envafolimab Add topic